


ATTENTION: ALL FACILITIES

Implementation of enoxaparin biosimilar - Redesca June 14, 2023

As part of the Health PEI Biosimilar Initiative, an enoxaparin biosimilar, **Redesca®**, will be implemented across Health PEI facilities on **June 14, 2023**. A biosimilar is a highly similar version of a biologic drug that comes onto market after the patent on the originator or reference biologic drug has expired

The Provincial Drugs and Therapeutics Committee (PD&T) has endorsed the selection of Redesca® as the preferred biosimilar **to be used in place of Lovenox®** in Health PEI facilities.

A therapeutic interchange to replace orders for Lovenox® with Redesca® at the same dose and frequency has also been approved by PD&T. Clinical Information System (CIS) functionality will be used to automatically implement the interchange for electronic orders.



The “Lovenox” and “enoxaparin (Lovenox)” orderables will remain available. However, when selected, **will be automatically interchanged** to “enoxaparin (Redesca).”

Within electronic PowerPlans, the synonym “enoxaparin (Lovenox)” will be replaced by “enoxaparin (Redesca)”

On June 14, **following the morning administration**, any active orders for Lovenox® will be interchanged to Redesca® by pharmacy staff at each facility. Pharmacy staff will coordinate with nursing staff in patient care areas to make the required changes in enoxaparin wardstock.

Please contact your facility's Pharmacy Department if you have any related questions.